TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Halozyme ( (HALO) ).
On November 18, 2025, Halozyme Therapeutics, Inc. announced a transition plan involving Nicole LaBrosse, the Senior Vice President and Chief Financial Officer. LaBrosse will continue in her role until a new CFO is hired or until March 30, 2026, after which she will depart for a new opportunity. The Transition and Release Agreement outlines benefits for LaBrosse, including a 2025 bonus, severance payment, and equity award vesting, contingent on her compliance with the agreement’s terms.
The most recent analyst rating on (HALO) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.
Spark’s Take on HALO Stock
According to Spark, TipRanks’ AI Analyst, HALO is a Outperform.
Halozyme’s strong financial performance and positive earnings call are the primary drivers of its high score. The company’s robust revenue growth and raised guidance reflect confidence in its strategic direction. Technical analysis presents mixed signals, and while the valuation is reasonable, high leverage remains a risk.
To see Spark’s full report on HALO stock, click here.
More about Halozyme
Average Trading Volume: 2,152,710
Technical Sentiment Signal: Strong Buy
Current Market Cap: $8.27B
See more data about HALO stock on TipRanks’ Stock Analysis page.